Ripretinib
Qinlock (ripretinib) is an oral prescription tablet that acts as a kinase inhibitor, targeting enzymes like KIT and PDGFR alpha to help manage certain cancers. Manufactured by Deciphera Pharmaceuticals, LLC, it comes in 50 mg doses. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Qinlock (ripretinib) is an oral prescription tablet that acts as a kinase inhibitor, targeting enzymes like KIT and PDGFR alpha to help manage certain cancers. Manufactured by Deciphera Pharmaceuticals, LLC, it comes in 50 mg doses. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Ripretinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Ripretinib — ANDA 213973 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213973"
}
]
|
| identifier | ANDA213973 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"drug-safety",
"medications",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Ripretinib |
